

COVID-19 Update – July 2, 2020

COVID-19 Treatment Coverage

MVP Health Care® (MVP) has extended the Member cost-share waiver for COVID-19 treatment costs for any site of service, including inpatient hospitalizations and emergency room visits, for New York fully insured health plans and Medicare health plans **through 9/7/2020**. Medicare MSA Members must first meet their deductible to achieve \$0 cost-share. The Member cost-share waiver for Vermont fully insured health plans has been extended until the State of Emergency is lifted. Self-funded employer groups have the option to waive COVID-19 treatment costs for their plan participants.

To ensure Member cost-share is waived for all applicable Members, bill the following code **as the primary diagnosis** for the **treatment of COVID-19**:

Diagnosis Code	Description
U07.1	COVID-19, virus identified

COVID-19 Diagnostic and Antibody Testing

MVP will continue to cover COVID-19 diagnostic testing and antibody testing until the State of Emergency is lifted. Although MVP does not consider occupational testing for COVID-19 to be a covered, medically necessary health plan benefit, we are closely following discussions at the state and federal level about this issue.

Claims billed with the following ICD-10 codes **as the primary diagnosis** for office, Emergency Department, or Urgent Care Center visits that are for the **primary purpose of diagnostic testing** will not apply a cost-share:

- Z03.818
- Z20.828

In addition, the following codes will be covered at **no cost-share for commercial Members**:

- R05
- R06.02
- R50.9

When antibody testing is performed, the following codes will ensure Member cost-share is waived:

CPT Code	Description
86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19)
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19)

To view a summary of all updates, visit mvphealthcare.com/Providers/COVID19.

To receive future FastFax messages by email, send a request to MVPFastFax@mvphealthcare.com.

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.



In addition, the following lab codes will also be covered at **no cost-share to the member**:

CPT Code	Description
87631	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19), amplified probe technique
U0001	Reported for coronavirus testing using the Centers for Disease Control and Prevention (CDC) 2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel.
U0002	Reported for validated non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19).
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.
U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.

To view all faxed messages, visit mvphealthcare.com/FastFax.

To receive future FastFax messages by email, send a request to MVPFastFax@mvphealthcare.com.

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

